Resistance to Experimental Autoimmune Encephalomyelitis and Impaired IL-17 Production in Protein Kinase Cθ-Deficient Mice

The protein kinase Cθ (PKCθ) serine/threonine kinase has been implicated in signaling of T cell activation, proliferation, and cytokine production. However, the in vivo consequences of ablation of PKCθ on T cell function in inflammatory autoimmune disease have not been thoroughly examined. In this study we used PKCθ-deficient mice to investigate the potential involvement of PKCθ in the development of experimental autoimmune encephalomyelitis, a prototypic T cell-mediated autoimmune disease model of the CNS. We found that PKCθ−/− mice immunized with the myelin oligodendrocyte glycoprotein (MOG) peptide MOG35–55 were completely resistant to the development of clinical experimental autoimmune encephalomyelitis compared with wild-type control mice. Flow cytometric and histopathological analysis of the CNS revealed profound reduction of both T cell and macrophage infiltration and demyelination. Ex vivo MOG35–55 stimulation of splenic T lymphocytes from immunized PKCθ−/− mice revealed significantly reduced production of the Th1 cytokine IFN-γ as well as the T cell effector cytokine IL-17 despite comparable levels of IL-2 and IL-4 and similar cell proliferative responses. Furthermore, IL-17 expression was dramatically reduced in the CNS of PKCθ−/− mice compared with wild-type mice during the disease course. In addition, PKCθ−/− T cells failed to up-regulate LFA-1 expression in response to TCR activation, and LFA-1 expression was also significantly reduced in the spleens of MOG35–55-immunized PKCθ−/− mice as well as in in vitro-stimulated CD4+ T cells compared with wild-type mice. These results underscore the importance of PKCθ in the regulation of multiple T cell functions necessary for the development of autoimmune disease.

[1]  T. So,et al.  Protein Kinase Cθ Controls Th1 Cells in Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.

[2]  M. Bachmann,et al.  Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Hunter.  New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions , 2005, Nature Reviews Immunology.

[4]  Peter B. Dias,et al.  Protein Kinase C θ Is Not Essential for T-Cell-Mediated Clearance of Murine Gammaherpesvirus 68 , 2005, Journal of Virology.

[5]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[6]  S. Gaffen,et al.  Crucial Role for Nuclear Factor of Activated T Cells in T Cell Receptor-mediated Regulation of Human Interleukin-17* , 2004, Journal of Biological Chemistry.

[7]  T. So,et al.  Differential Regulation of Th2 and Th1 Lung Inflammatory Responses by Protein Kinase Cθ1 , 2004, The Journal of Immunology.

[8]  D. Littman,et al.  Protein Kinase C θ Is Critical for the Development of In Vivo T Helper (Th)2 Cell But Not Th1 Cell Responses , 2004, The Journal of experimental medicine.

[9]  D. Gambi,et al.  Decreased integrin gene expression in patients with MS responding to interferon-β treatment , 2004, Journal of Neuroimmunology.

[10]  N. Hogg,et al.  How T cells use LFA-1 to attach and migrate. , 2004, Immunology letters.

[11]  Russell G. Jones,et al.  PKCθ Signals Activation versus Tolerance In Vivo , 2004, The Journal of experimental medicine.

[12]  R. Vita,et al.  SPAK kinase is a substrate and target of PKCθ in T‐cell receptor‐induced AP‐1 activation pathway , 2004, The EMBO journal.

[13]  G. Baier,et al.  Protein Kinase C (cid:2) Affects Ca 2 (cid:3) Mobilization and NFAT Cell Activation in Primary Mouse T Cells , 2022 .

[14]  G. Baier.  The PKC gene module: molecular biosystematics to resolve its T cell functions , 2003, Immunological reviews.

[15]  B. Engelhardt,et al.  Encephalitogenic T cells use LFA‐1 for transendothelial migration but not during capture and initial adhesion strengthening in healthy spinal cord microvessels in vivo , 2002, European journal of immunology.

[16]  Michael Loran Dustin,et al.  T-cell activation: a multidimensional signaling network. , 2002, Current opinion in cell biology.

[17]  D. Littman,et al.  Protein kinase C-θ: signaling from the center of the T-cell synapse , 2002 .

[18]  A. Altman,et al.  PROTEIN KINASE C IN T CELL ACTIVATION , 2002 .

[19]  I. Singh,et al.  Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis , 2001, Journal of neuroscience research.

[20]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[21]  A. Altman,et al.  Protein Kinase C-θ Mediates a Selective T Cell Survival Signal Via Phosphorylation of BAD1 , 2001, The Journal of Immunology.

[22]  A. Altman,et al.  Protein kinase C-theta mediates a selective T cell survival signal via phosphorylation of BAD. , 2001, Journal of immunology.

[23]  H. Hameister,et al.  T cell expressed PKCθ demonstrates cell‐type selective function , 2000 .

[24]  C. Bertolotto,et al.  Protein Kinase C θ and ε Promote T-cell Survival by a Rsk-dependent Phosphorylation and Inactivation of BAD* , 2000, The Journal of Biological Chemistry.

[25]  W. Greene,et al.  Protein Kinase C-θ Participates in NF-κB Activation Induced by CD3-CD28 Costimulation through Selective Activation of IκB Kinase β , 2000, Molecular and Cellular Biology.

[26]  H. Himmelbauer,et al.  Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand , 2000, European journal of immunology.

[27]  A. Altman,et al.  NF-κB activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-θ , 2000 .

[28]  A. Altman,et al.  NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Flavell,et al.  Cell fate decision: T-helper 1 and 2 subsets in immune responses , 2000, Arthritis research.

[30]  E. Schaeffer,et al.  PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes , 2000, Nature.

[31]  G. Grau,et al.  Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity , 1997, Neuroreport.

[32]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[33]  B. Trapp,et al.  Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. , 1996, Journal of neuropathology and experimental neurology.

[34]  M. Miyasaka,et al.  Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. , 1996, Journal of Immunology.

[35]  H. Grunicke,et al.  Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes , 1996, Molecular and cellular biology.

[36]  Y. Ron,et al.  Bothanti-CD11a(LFA-l) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis , 1995, Journal of Neuroimmunology.

[37]  K. Murphy,et al.  The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model , 1995, The Journal of experimental medicine.

[38]  T. Owens,et al.  The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. , 1995, Neurologic clinics.

[39]  Y. Ron,et al.  Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. , 1995, Journal of neuroimmunology.

[40]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.